Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott J. Rodig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Scott Rodig and Olga Pozdnyakova.
Connection Strength

1.140
  1. Emerging targeted therapies for lymphoid malignancies. Arch Pathol Lab Med. 2012 May; 136(5):476-82.
    View in: PubMed
    Score: 0.515
  2. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294.
    View in: PubMed
    Score: 0.167
  3. The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. Leukemia. 2015 Jan; 29(1):241-4.
    View in: PubMed
    Score: 0.155
  4. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol. 2014 Nov; 27(11):1447-54.
    View in: PubMed
    Score: 0.151
  5. Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Mod Pathol. 2020 07; 33(7):1380-1388.
    View in: PubMed
    Score: 0.057
  6. Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish. Dis Model Mech. 2019 05 07; 12(5).
    View in: PubMed
    Score: 0.054
  7. Surface Light Chain Expression in Primary Mediastinal Large B-Cell Lymphomas by Multiparameter Flow Cytometry. Am J Clin Pathol. 2015 Oct; 144(4):635-41.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.